A mere four days after announcing a potential link-up, troubled US group Nektar Therapeutics and UK healthcare holding company PureTech have called off merger talks which had taken seasoned observers of biotech M&A activity by surprise.
Nektar And PureTech Merger Talks Terminated
Discussions Could Have Caused 'Extended Period Of Uncertainty'
The UK’s PureTech and US biotech Nektar have ended discussions about a potential merger which analysts did not see coming, but a deal could still happen and other companies may also make a move.

More from Deals
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.